Trimethylglycine Injection

Generic Name: Trimethyl glycine (TMG) / Betaine
Chemical Class: Methylated derivative of glycine; organic osmolyte; methyl-group donor.
Physiological Role:

• Key Osmo protectant in cells
• Major participant in methylation reactions
• Converts homocysteine → methionine via betaine-homocysteine methyltransferase
• Supports detoxification, liver function, and cellular hydration

Route of Administration:

• Primarily oral.
• IV use is non-standard and typically restricted to:
  • Research settings
  • Specialized metabolic disorders
  • Compounded preparations in metabolic crises (rare)

Clinical Uses (Oral Standard):

• Treatment of homocystinuria (FDA-approved)
• Supportive therapy for fatty liver and methylation deficits
• Experimental uses in mitochondrial and metabolic disorders

Clinical Uses (IV — Experimental or Rare):

• Severe metabolic crises where oral administration is impossible
• Acute lowering of dangerously high homocysteine (non-routine)
• Osmotherapy or hepatic metabolic support (investigational)

⚠ No standard or FDA-approved IV dosage exists.
The following information is extrapolated from pharmacology data and metabolic requirements.

A. Adult IV Dosage (Experimental/Literature-Supported)

• 100–300 mg/kg/day IV, divided in continuous infusion
• Typically dissolved in sterile solution and infused over 4–12 hours
• Adjustments based on serum homocysteine and methylation markers

B. Oral-to-IV Conversion Considerations

Oral betaine doses for homocystinuria:

• 6–12 g/day

IV dosing (if considered) attempts to mirror bioavailability, thus:

• 6–10 g/day IV infusion would approximate therapeutic methylation support.

C. Administration

• Must be compounded under sterile conditions
• Infuse via peripheral or central IV line depending on osmolarity
• Avoid bolus administration
• Continuous monitoring required

MECHANISMS OF ACTION

A. Methyl Group Donor (Primary Mechanism)

Betaine → donates a methyl group →
Homocysteine → Methionine
(via betaine-homocysteine methyltransferase)

This leads to:

• Reduction in plasma homocysteine
• Increased methionine and S-adenosylmethionine (SAMe)
• Improved methylation capacity for DNA, RNA, proteins, lipids, neurotransmitters

B. Osmoprotectant / Cellular Hydration

Betaine acts as a compatible osmolyte:

• Protects cells during dehydration
• Maintains cellular volume
• Stabilizes proteins and enzymes
• Protects mitochondria against osmotic and oxidative stress

C. Hepatic Function Support

• Enhances fat metabolism
• Supports phosphatidylcholine synthesis via methylation
• Reduces hepatic steatosis (non-alcoholic fatty liver disease clinical use orally)

D. Glycine Derivative for Metabolic Pathways

Betaine indirectly contributes to:

• Creatine synthesis
• Carnitine synthesis
• Detoxification pathways
• Neurotransmitter formation

E. Impact on Mitochondrial Efficiency

Betaine improves:

• Mitochondrial respiration
• Oxidative stress resilience
• ATP generation (indirectly via methylation pathways)

Absolute Contraindications

1. Known hypersensitivity to betaine or components
2. Severe renal impairment with risk of accumulation
3. Hyper-methioninemia (>1000 µmol/L) – betaine increases methionine levels
4. Homocystinuria with existing cerebral edema
   1. High methionine can worsen edema

Relative Contraindications

• Severe hepatic impairment (risk of methionine accumulation)
• Uncontrolled cardiovascular disease (rapid methylation shifts can alter lipid levels)
• Psychiatric disorders (methylation changes influence neurotransmitters)
• Pregnancy (high methylation burden may be harmful—use cautiously IV)

Monitoring

Mandatory when using IV betaine:

• Serum homocysteine
• Plasma methionine levels
• Liver function tests
• Renal function
• Serum electrolytes
• CNS monitoring (increased methionine → brain edema risk)

SAMe / SAH ratios if available

Drug Interactions

1. Methionine supplementation → excessive methionine accumulation
2. Serotonergic agents / antidepressants:
   1. Changes in methylation can alter neurotransmitter metabolism
3. Valproic acid:
   1. Can increase homocysteine; betaine may counteract but must be monitored
4. Folate and B12 therapy:
   1. Strong synergistic homocysteine-lowering effect
5. Choline or phosphatidylcholine supplements:
   1. Additive methylation effects

Nutritional Interactions

• Low folate/B12 levels reduce betaine efficacy
• Excessive protein intake raises homocysteine burden
• TMG interacts with osmotic balance, so electrolyte monitoring is crucial

Common

• Gastrointestinal discomfort (less relevant IV)
• Headache
• Mild hypotension
• Sweating or warmth during infusion
• Body odor (“fishy smell”) from methylamine metabolites

Metabolic

• Elevated methionine levels (most important risk)
• Possible neurological symptoms if methionine >1000 µmol/L
• Electrolyte disturbances (due to osmotic effects)
• Altered lipid profiles

Serious

• Cerebral edema (high methionine—rare but serious)
• Seizures (secondary to metabolic imbalance)
• Cardiac arrhythmias (electrolyte shifts)
• Hepatic strain in chronic use

Overdose

• Severe hypermethioninemia
• CNS toxicity
• Osmotic demyelination risk if infused too rapidly

Pregnancy

• Oral betaine classification: Generally safe when necessary
• IV use is not recommended, due to:
  • Lack of safety data
  • Potential methionine elevation
  • Unknown fetal methylation impacts

Use only if benefit outweighs risk in severe metabolic cases.

Breastfeeding

• No evidence of harm at nutritional doses
• Unknown transfer via IV administration

Monitor infant for irritability or feeding issues if maternal metabolic levels are high

For compounded IV betaine solutions:

• Temperature: 20–25°C (68–77°F)
• Protect from moisture; hygroscopic compound
• Store in airtight containers
• Protect from light (recommended)
• Use sterile technique for preparation
• Shelf life depends on compounding pharmacy standards (typically < 7 days refrigerated)
• Inspect for:
  • Precipitates
  • Cloudiness
  • Discoloration
  • Particulate matter

Do not use if solution integrity is compromised.

(Professional clinical sources—no URLs)

1. FDA Label: Betaine Anhydrous for Homocystinuria – Prescribing Information.
2. S. Pharmacopeia (USP) – Monographs for Betaine.
3. Mudd SH et al. Disorders of Transsulfuration and Methylation. Metabolic Textbook.
4. Clinical Pharmacology of Betaine and Methyl Group Donors – Peer Review Articles.
5. ASPEN: Guidelines for Specialized Nutrition Support in Metabolic Disorders.
6. Medical Biochemistry: Methylation Cycle & Betaine-Homocysteine Methyltransferase.
7. Hepatic Metabolism Texts – Role of Betaine in Fatty Liver and Methionine Pathways.